BioSymetrics is a technology company that specializes in advanced biometric identification and authentication solutions. The company leverages artificial intelligence and machine learning to provide secure, fast, and user-friendly biometric systems that can be integrated into various applications across different industries.

Gabriel Musso

Anthony Iacovone

BioSymetrics

BridgeBio Pharma is a self-described biopharmaceutical company focused on developing and commercializing transformative medicines for serious diseases. It focuses on gene-based and genetic medicine.

BridgeBio Pharma

Maven Asset Management provides solutions for asset management challenges using IBM Maximo products. Services include implementation, upgrades, consulting, and support.

Maven Asset Management

BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicines. 

We partner with leading healthcare and life science companies, such as Northwell Health, Janssen, Sema4, and Mt. Sinai, to increase our understanding of disease and find better drugs faster. 

We use a patent pending, machine learning technology called Contingent-AI™ to address bias detection and correction during pre-processing stages of machine learning and identify additional feature sets for analysis that are contingent upon decisions made during bias reduction.

We combine this technology with an experimental practice that uniquely combines in silico and in vivo work to produce a faster, more precise set of predictive results for drug discovery research.

We are a remote-first company with people clusters in Toronto and Boston. We are actively hiring. For more information, please visit our website at www.biosymetrics.com. 

#ArtificialIntelligence #AI #MachineLearning #Biotech #Healthcare #DataAnalytics #BigData #PrecisionMedicine #Pharma #LifeSciences #Genomics #DigitalHealth #DrugDiscovery #MedTech

AJI Capital

We're excited for Gabriel Musso, our Co-Founder and Chief Scientific Officer, to present at MassBio 2024 Align Summit on April 25th, with insights by McKinsey & Company & Locust Walk Partners. This is a valuable opportunity to gain insights and network within the biotech community.  

Register here: https://lnkd.in/euynZvkA 

#AlignSummit24

Join our co-founder, Gabriel Musso, at the BIO CEO & Investor Conference - one of the largest investor conferences in our industry where institutional investors, industry analysts, and senior executives are shaping the future investment landscape of biotechnology. Still a few spots available for one-on-one meetings.

#bioceo24 #ai #drugdiscovery

https://bcic.bio.org/

The second Monday of February is International Epilepsy Day, a day for raising awareness and listening to the experiences of the millions of people worldwide with epilepsy. At BioSymetrics we are proud to be contributing to the fight against epilepsy, and will continue to apply our platform to expedite the advancement of therapeutics that address the unmet symptoms of epilepsy patients. You can learn more about International Epilepsy Day at the link below.

#epilepsyday

https://lnkd.in/eCBMUZtK

Thank you Genetic Engineering & Biotechnology News for this insightful piece on the use of AI for Drug Development. Glad we were able to take part among leaders from Salve Therapeutics, Biolexis Therapeutics, Inc. and NVIDIA.   Take a read through to hear our Chief Scientific Officer Gabriel Musso's take on the importance of phenomics in AI-based Drug Discovery.

#ai, #drugdiscovery

https://lnkd.in/gbWRfT2m

⏱ Meet with us next week during JPM in San Francisco!

Emilie T.E. Gross PhD, MBA will be attending the Neuroscience Innovation Forum and BIO @ JPM Week 2024.

Stacie Calad-Thomson will be attending Biotech Showcase and participate in a panel discussion on "The Therapeutics of Tomorrow ML+ AI in Drug Discovery" on Tuesday, January 9th. 

We only have a few time slots left. If you're interested in learning about our recent developments and exploring potential partnerships related to our CNS programs and AI-phenomics platform, don't miss this opportunity!

🗓 J.P. Morgan is just around the corner! Meet us during J.P. Morgan week starting Monday, January 8th in San Francisco. Stacie Calad-Thomson, Chief Strategy Officer and Head of Drug Discovery at BioSymetrics, and Emilie T.E. Gross PhD, MBA, Director of Business Development, will be attending.

👉 Emilie will also be available through BIO Partnering @ JPM Week 2024 with a few time slots remaining on her calendar. If you're interested in learning about our recent developments and exploring potential partnerships related to our CNS programs and AI-phenomics platform, don't miss this opportunity!

Use the following link to book a meeting with Emilie on the BIO platform:

https://lnkd.in/gV4G7v33

🏁 Join us at the 7th Annual Neuroscience Innovation Forum (#Sachs_NIF) on January 7th at the Marines Memorial Club, San Francisco, where you'll have the opportunity to connect with Emilie T.E. Gross PhD, MBA, who will be discussing exciting developments within BioSymetrics' CNS pipeline and AI/ML-Phenomics platform.

Don't miss out on this opportunity for outstanding high-level keynotes and panel discussions addressing the important advances in CNS therapeutic management, neurotech and diagnostics.

📅 Scheduling for one-on-one partnering meetings opens on December 18th!

https://lnkd.in/e5x7uiGK

The potential of AI in advancing precision medicine hinges significantly on high-quality datasets from patients. The establishment of a unified patient record emerges as a crucial prerequisite for the forthcoming AI advancements in the field of medicine.

But why hasn't a unified patient record been developed yet?

Engage in a dialogue on the topic of a unified health record by participating in this panel discussion featuring The Alliance for Artificial Intelligence in Healthcare (AAIH) members. The event is scheduled for 12 PM EST/ 9 AM PST today!

#ai #healthcare

Metric
Company Name	BioSymetrics	BridgeBio Pharma	Maven Asset Management
Symbol
MSH ID	COM:BIOSYMETRICS	COM:BRIDGEBIOPHARMA	COM:MAVENASSET
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Technology	Healthcare & Health Services	Commercial & Professional Services
Industry	Biometric Technology	Biotechnology	Asset Management
Country	US	US	US
Stage		Post-IPO Equity
Employee Count	22
Website	biosymetrics.com	bridgebiopharma.com	mavenasset.com
LinkedIn	biosymetrics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		23.81K
Web Traffic Growth		0.19
Valuation
Raised Capital		250M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:BIOSYMETRICS

BioSymetrics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue